CHI Collaborates: Protecting Reimbursement
CMS proposed to change reimbursement for FDA-approved products that promote wound healing to the same rate as basic wound management products (akin to “bundling biologics with bandages”).
CHI supported efforts to engage manufacturers, patient groups and providers in opposing the draft payment scheme. CHI also spearheaded a letter signed by nearly two dozen members of California’s Congressional delegation urging CMS to differentiate reimbursement for clinically tested, FDA-approved advanced wound care treatments versus conventional wound management products.
CMS changed their final payment scheme to reimburse the FDA-approved treatments at 60% higher than initially proposed.
CHI Keeps You Informed